Micropulse laser treatment study

In patients with Diabetic Maculopathy, is micropulse laser treatment, better than argon laser treatment, at improving or stabilising visual acuity and reducing retinal oedema?

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000369325

Enrollment

Registered

2008-07-30

Start date

2008-04-23

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary purpose of the study is to determine if in patients with Diabetic Maculopathy micropulse laser treatment is better than argon laser treatment, at improving or stabilising visual acuity and reducing retinal oedema. The hypothesis is that the micropulse laser may provide as good or better therapeutic benefit as compared to current treatments but without the damage normally associated with this treatment.

Interventions

Micropulse laser, single treatment, via slit-lamp microscope. One eye with condition to be treated. The radiant exposure of the laser will be 70 - 120mJ/cm2 per treatment spot. Treatment duration 10 to 30 minutes. Overall intervention period will be 1yr.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Type 2 diabetes Focal or diffuse macular oedema

Exclusion criteria

Previous laser treatment Proliferative retinopathy

Outcome results